American Oncology Institute (AOI) at ASCOMS Jammu has achieved a significant breakthrough in complex cancer treatment by ...

When doctors told the father of two his cancer was seen just three times a year in Oregon, he found a lifeline 2,000 miles ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

The “Control” singer—who in 2024 shared her diagnoses with lupus and a rare T-cell lymphoproliferative disorder, an umbrella term for diseases related to the overproduction of white blood cells—gave ...

Northwestern Medicine announced Tuesday that for the first time, its doctors have successfully treated metastatic eye cancer using a method that delivers chemotherapy directly to the liver. The ...

Cemiplimab plus chemotherapy was found to be consistently effective in treating non-small cell lung cancer (NSCLC) and held up in the EMPOWER-Lung 3 trial. Prior efficacy results for overall survival ...

MammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer. High-risk patients benefit significantly from chemotherapy, while low-risk ...

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in ...

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients ...

Poster: LX9211, a Novel AAK1 Inhibitor, Alleviates Pain in Preclinical Models of Chemotherapy-induced Neuropathic Pain and Multiple Sclerosis Date: Saturday, September 6, 2025 Time: 8:30 a.m. – 6:00 p ...

Cancer patients undergoing chemotherapy may soon have a new option to try to keep their hair — a shampoo-like gel that could protect hair from falling out during chemo. Baldness from ...